Maxwell News
MaxWell Biomedical Featured in the MedTech Strategist’s “AF Symposium 2023: Experts Debate Cosmic Questions”.
“This is a new modality. It may serve as a single modality or a hybrid, where you link it with ablation. Let's say ablation only gets you halfway there. With pacing, you add another level of therapy and perhaps another level of success”, say Douglas Packer, MD renowned EP.
At the AF Symposium, MedTech Strategist had the opportunity to meet with Randy Werneth, co-founder of MaxWell Biomedical (San Diego, CA), a start-up developing a first-of-its-kind anti-AF pacing solution called Spatial Resynchronization Therapy (SRT) for the restoration of sinus rhythm.
Released: 2023
Maxwell Biomedical Completes Acquisition of Cardialen’s Assets.
Acquisition expands the Maxwell Biomedical product and intellectual property portfolio.
SAN DIEGO, Calif., December 14 2022 Maxwell Biomedical announced today that it has completed the acquisition of Cardialen’s assets. Cardialen, a Minneapolis, MN based company developed MultiPulse™ Therapy (MPT™), a low-energy defibrillation and cardioversion therapy designed to treat atrial fibrillation (AFib) and ventricular tachycardia (VT).
Released: 2022
Maxwell Biomedical Completes First-in-Human Study Enrollment and Testing of Spatial Resynchronization™ Therapy
Spatial Resynchronization Therapy (SR™T) demonstrates proof-of-concept in repeatedly terminating atrial fibrillation (AFib) and restoring sinus rhythm
SAN DIEGO, Calif., October 20 2022 Maxwell Biomedical announced that it has successfully completed enrollment in their First-in-Human Clinical Trial “Initial Experience with Spatial Resynchronization Therapy in Patients with Atrial Fibrillation (NCT 05461612)” being conducted at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia. SRT is a device-based approach that features a proprietary algorithm for diagnosing and treating AFib.
Released: 2022
Maxwell Biomedical is Awarded a Phase I Small Business Innovation Research (SBIR) Grant for its Spatial Resynchronization Therapy Device
Grant money will be used to support the research and development of Spatial Resynchronization™ Therapy (SR™T) to treat atrial fibrillation (AFib)
SAN DIEGO, Calif., September 15 2022. Maxwell Biomedical announced today that is has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Heart Lung and Blood Institute (NIH) to pursue development and testing of their proprietary SRT device designed specifically to diagnose and treat AFib. Phase I SBIR grants are awarded to small businesses to establish the technical merit, feasibility, and commercial potential of the proposed product.
Released: 2022
Maxwell Biomedical Initiates First-in-Human Trial to Assess the Safety and Efficacy of a Novel Pacing Intervention in Patients with Atrial Fibrillation.
Spatial Resynchronization Therapy (SRT) Successfully Terminated Atrial Fibrillation
SAN DIEGO, Calif., July 14, 2022. Maxwell Biomedical announced today that it has initiated its First-in Human Clinical Trial “Initial Experience with Spatial Resynchronization Therapy in Patients with Atrial Fibrillation (SR-TheAF)” at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia. NCT05461612.
Released: 2022
New Wireless Pacemaker Could Prevent Common Complications
The newest, smallest pacemaker comes with no strings attached—literally.
Nearly 190,000 Americans received a pacemaker in 2009. The devices have traditionally required a battery pack, embedded just below the collarbone, with leads that thread through the veins and into the heart. But “leads cause infection, and they’re big, and they cause complications,” says head researcher Aydin Babakhani of Rice University.
Published: 2017